Search results
Results From The WOW.Com Content Network
The medical-industrial complex describes the conflict of interest present between physicians and the healthcare industry. [10] Physicians who invest in medical device companies may be biased towards certain medical devices or treatments, creating a conflict of interest between doing what is best for a patient versus what is in their best ...
The group tries to get healthcare providers to sign the No Free Lunch pledge.Health care professionals who take the pledge agree to: accept no money, gifts, or hospitality from the pharmaceutical industry; to seek unbiased sources of information and not rely on information disseminated by drug companies; and to avoid conflicts of interest in [their] practice, teaching, and/or research.
The goal of the law is to increase the transparency of financial relationships between health care providers and pharmaceutical manufacturers and to uncover potential conflicts of interest. [1] The bill allows states to enact "additional requirements", as six states already had industry-pay disclosure laws. [2]
“The crux of the issue is the conflict of interest,” says Rob Andrews, a former congressman from New Jersey who now leads the Health Transformation Alliance, a coalition of large self-insured ...
For instance, an employee of a pharmaceutical company possesses a potential conflict of interest regarding that company and its products. However, it only becomes an actual conflict only if they choose to edit the associated article, engage in discussions about it, or make edits about rival products.
Most of the documents on DIDA were made public as a result of lawsuits against pharmaceutical companies Parke-Davis, Warner-Lambert, Pfizer, Merck & Co., Wyeth and Abbott Labs, among others. DIDA was founded in 2005 with the support of a gift by Thomas Greene, the attorney for David Franklin , whistleblower in United States ex rel. Franklin v.
Robert F. Kennedy Jr., the newly confirmed HHS secretary, has opposed pharmaceutical user fees, saying they create a barrier for smaller companies to gain approval for their technologies.
Trump, through his agenda, pledges to end pharmaceutical shortages and “return the manufacture of life-saving drugs to the United States” by restoring his 2020 Executive Order 13944 ...